New Nanoprobe for Breast Cancer Cell Imaging Based on Low-Density Lipoprotein Publisher Pubmed



Mirzaei M^{1, 2} ; Mohseni M^{3, 4} ; Iranpour Anaraki N⁴ ; Mohammadi E⁴ ; Safari S⁵ ; Mehravi B^{3, 4, 6} ; Ghasempour A³ ; Pourdakan O³ Show Affiliations
Source: Artificial Cells# Nanomedicine and Biotechnology Published:2020

Abstract

Many malignant cancers have an increased demand for lipoprotein due to the requirement for lipids for the rapid proliferation of the tumours and which is met by the increased availability of LDL through upregulation of LDL transporters. This unique phenomenon is the basis for the use of LDL based nanoparticles for cell imaging. In this study, a novel MR-active LDL nanoparticle was synthesised as the MRI probes. This MR-active LDL was characterised by using different techniques including scanning electron microscopy (SEM), dynamic light scattering (DLS), Fourier-transform infra-red spectroscopy (FTIR) and magnetic resonance imaging (MRI). The intracellular uptake of Gd3+ and cytotoxicity was measured by ICP-AES and MTT assay respectively. Results suggest that this nanoprobe with spherical shape and size of 55 nm has reduced relaxation time compared to commercial contrast agent and is introduced as an appropriate imaging probe. The amount of reabsorption of nanoprobe increased up to 6 h and given that the connection of the chelator does not have an effect on reabsorption proves that entry through transporter of APO section has done. This study lays the basis for exploring a personalised medicine strategy by directing a patient’s own LDL to cancer cell imaging in the early stages. © 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.